Volitionrx Ltd (VNRX) Stock Price & Analysis
Volitionrx Ltd (VNRX) fell 2.16% to USD 1.36 as of June 10, 2026 at 07:20 UTC, according to Nexqual real-time market data.
VNRX last closed at USD 1.39; the session ranged USD 1.3–1.44 on volume of 377,776 shares. Market capitalization is $11.73M, with a 52-week range of USD 1.3–18.8 (ASE). Source: Nexqual, June 10, 2026 at 07:20 UTC.
Key Statistics (as of June 10, 2026 at 07:20 UTC)
| Price | USD 1.36 |
|---|---|
| Change | ▼ 2.16% (down) |
| Previous Close | USD 1.39 |
| Open | USD 1.4 |
| Day Range | USD 1.3 – 1.44 |
| 52-Week Range | USD 1.3 – 18.8 |
| Volume | 377,776 shares |
| Market Cap | $11.73M |
| Exchange | ASE |
Technical Analysis (VNRX)
Nexqual's technical model rates VNRX "SELL" based on 3 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.9 (oversold) |
| vs SMA50 | Below (USD 2.82) |
| MACD | -0.25 (negative) |
Analyst Ratings (VNRX)
Wall Street analysts rate VNRX "Strong Buy" based on 4 analysts, with a mean price target of USD 20.21 (range USD 16.83–24), per Nexqual as of June 10, 2026 at 07:20 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 20.21 |
| High Target | USD 24 |
| Low Target | USD 16.83 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (VNRX)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $466,610 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.84 vs est -0.73 ▼ miss |
| 2025-12-31 | USD -0.91 vs est -0.8 ▼ miss |
| 2025-09-30 | USD -1.06 vs est -1.04 ▼ miss |
| 2025-06-30 | USD -1.31 vs est -1 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
Financials & Fundamentals (VNRX)
| Total Revenue | $2.47M |
|---|---|
| Revenue Growth (YoY) | +299.80% |
| Gross Margin | +100.00% |
| Operating Margin | -542.99% |
| Profit Margin | +0.00% |
| Current Ratio | 0.33 |
| Total Cash | $3.10M |
| Total Debt | $11.70M |
| Free Cash Flow | $-9.20M |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
Financial Health Score (VNRX)
Nexqual rates Volitionrx Ltd's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:20 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $12M debt |
| Cash Flow | Weak — FCF negative: -$9M, burning cash |
| Efficiency | Mixed — No data |
Ownership (VNRX)
| Insider Ownership | +11.58% |
|---|---|
| Institutional Ownership | +27.94% |
| Shares Outstanding | 8.63M |
| Float | 6.57M |
| Short % of Float | +4.77% |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
Leadership (VNRX)
Volitionrx Ltd is led by Cameron Reynolds (age 54), Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 07:20 UTC.
| Founder, CEO, President & Director | Cameron Reynolds (age 54) |
|---|---|
| Chief Operating Officer | Gaetan Michel (age 52) |
| CFO & Treasurer | Terig Hughes (age 55) |
| Chief Scientific Officer | Jacob Vincent Micallef (age 69) |
| Group Chief Marketing & Communications Officer | Louise Batchelor Day (age 54) |
Major Backers & Investors (VNRX)
Notable institutional backers of Volitionrx Ltd include Lagoda Investment Management, L.P., Fidelity, Luminus Management, LLC, according to Nexqual as of June 10, 2026 at 07:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lagoda Investment Management, L.P. | 9.36% |
| Fidelity | 0.61% |
| Luminus Management, LLC | 0.58% |
| Silverberg Bernstein Capital Management LLC | 0.15% |
| Wealthspire Advisors, LLC | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.47% |
| Geode Capital | 0.71% |
| State Street | 0.39% |
| BlackRock | 0.26% |
| Northern Trust | 0.15% |
Source: Nexqual, June 10, 2026 at 07:20 UTC.
From Volitionrx Ltd's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
- The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
- It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ECOR | electroCore, Inc. | USD 9.52 | ▲ 9.17% |
| MLSS | Milestone Scientific, Inc. | USD 0.39 | ▼ 8.1% |
| EVGN | Evogene Ltd. | USD 0.6 | ▼ 3.71% |
| IMDX | Insight Molecular Diagnostics I | USD 5.85 | ▲ 11.64% |
| NDRA | ENDRA Life Sciences Inc. | USD 4.42 | ▲ 4.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:20 UTC. This page is informational and not investment advice.